Join the Oncology Voice Network. Join for Free
Building Winning Oncology Teams That Last

Building Winning Oncology Teams That Last


Share This Article



Summary

In this episode of the Oncology Voice Network, Dr. Kirk Shepard sits down with Spencer Weneck and Christian Camp to break down what truly makes an oncology organization resilient, competitive, and future-ready.

How do leading pharma and biotech teams keep up with oncology’s relentless pace? In this episode of the Oncology Voice Network, Dr. Kirk Shepard sits down with Spencer Weneck and Christian Camp to break down what truly makes an oncology organization resilient, competitive, and future-ready. Hear firsthand insights into today’s most urgent challenges: navigating the shift from an employer to a candidate-driven market, adapting to patent cliffs and M&A waves, and outsmarting the industry’s unparalleled war for talent. Discover why talent development, cultural fit, and cross-functional leadership are make-or-break factors—and why so many companies lose their way by ignoring them. Get inspired by real-life examples, honest lessons from failure, and a deep dive into how shared learning environments like OVN are resetting industry standards. Listen now and future-proof your oncology team.

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Real-World Evidence in Oncology: Opportunities and Limitations
OVN Avatar Massimo Di Maio, Francesco Perrone, Pierfranco Conte

Real-World Evidence in Oncology: Opportunities and Limitations

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Accelerated drug approvals in oncology: Pros and cons
OVN Avatar Thakur, Sayanta & Lahiry, Sandeep

Accelerated drug approvals in oncology: Pros and cons

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Oncology approvals in 2020: a year of firsts in the midst of a pandemic
OVN Avatar Laleh Amiri-Kordestani & Richard Pazdur

Oncology approvals in 2020: a year of firsts in the midst of a pandemic

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Explore OVN